Cargando…
No major association between TGFBR1*6A and prostate cancer
Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far re...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521683/ https://www.ncbi.nlm.nih.gov/pubmed/15385056 http://dx.doi.org/10.1186/1471-2156-5-28 |
_version_ | 1782121843504709632 |
---|---|
author | Kaklamani, Virginia Baddi, Lisa Rosman, Diana Liu, Junjian Ellis, Nathan Oddoux, Carole Ostrer, Harry Chen, Yu Ahsan, Habibul Offit, Kenneth Pasche, Boris |
author_facet | Kaklamani, Virginia Baddi, Lisa Rosman, Diana Liu, Junjian Ellis, Nathan Oddoux, Carole Ostrer, Harry Chen, Yu Ahsan, Habibul Offit, Kenneth Pasche, Boris |
author_sort | Kaklamani, Virginia |
collection | PubMed |
description | Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the development of breast, colon and ovarian cancer. The association with prostate cancer has not yet been explored. A total of 907 cases and controls from New York City were genotyped to test the hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer. |
format | Text |
id | pubmed-521683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5216832004-10-12 No major association between TGFBR1*6A and prostate cancer Kaklamani, Virginia Baddi, Lisa Rosman, Diana Liu, Junjian Ellis, Nathan Oddoux, Carole Ostrer, Harry Chen, Yu Ahsan, Habibul Offit, Kenneth Pasche, Boris BMC Genet Research Article Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the development of breast, colon and ovarian cancer. The association with prostate cancer has not yet been explored. A total of 907 cases and controls from New York City were genotyped to test the hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer. BioMed Central 2004-09-22 /pmc/articles/PMC521683/ /pubmed/15385056 http://dx.doi.org/10.1186/1471-2156-5-28 Text en Copyright © 2004 Kaklamani et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kaklamani, Virginia Baddi, Lisa Rosman, Diana Liu, Junjian Ellis, Nathan Oddoux, Carole Ostrer, Harry Chen, Yu Ahsan, Habibul Offit, Kenneth Pasche, Boris No major association between TGFBR1*6A and prostate cancer |
title | No major association between TGFBR1*6A and prostate cancer |
title_full | No major association between TGFBR1*6A and prostate cancer |
title_fullStr | No major association between TGFBR1*6A and prostate cancer |
title_full_unstemmed | No major association between TGFBR1*6A and prostate cancer |
title_short | No major association between TGFBR1*6A and prostate cancer |
title_sort | no major association between tgfbr1*6a and prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521683/ https://www.ncbi.nlm.nih.gov/pubmed/15385056 http://dx.doi.org/10.1186/1471-2156-5-28 |
work_keys_str_mv | AT kaklamanivirginia nomajorassociationbetweentgfbr16aandprostatecancer AT baddilisa nomajorassociationbetweentgfbr16aandprostatecancer AT rosmandiana nomajorassociationbetweentgfbr16aandprostatecancer AT liujunjian nomajorassociationbetweentgfbr16aandprostatecancer AT ellisnathan nomajorassociationbetweentgfbr16aandprostatecancer AT oddouxcarole nomajorassociationbetweentgfbr16aandprostatecancer AT ostrerharry nomajorassociationbetweentgfbr16aandprostatecancer AT chenyu nomajorassociationbetweentgfbr16aandprostatecancer AT ahsanhabibul nomajorassociationbetweentgfbr16aandprostatecancer AT offitkenneth nomajorassociationbetweentgfbr16aandprostatecancer AT pascheboris nomajorassociationbetweentgfbr16aandprostatecancer |